Background In the elderly, traditional influenza inactivated vaccines are often only modestly
immunogenic, owing to immunosenescence. Given that adjuvantation is a means of …

Background: The elderly are at a higher risk of morbidity and mortality associated with
influenza infection than younger adults, but get less protection from conventional …

Background: The higher effectiveness of MF59®-adjuvanted trivalent influenza vaccine
(MF59-TIV) vs. nonadjuvanted TIV in preventing influenza-related hospitalizations was …

Aim Adjuvanted influenza vaccines can overcome the poor antibody response of
conventional non-adjuvanted vaccines in the elderly. We evaluated the immunogenicity …

Background Standard‐dose seasonal influenza vaccines often produce modest
immunogenic responses in adults≥ 65 years old. MF59 is intended to elicit a greater …

Annual circulation of influenza virus coincides with a peak in cardiovascular and pneumonia
mortality/morbidity. This study aimed to determine the effectiveness of MF59™-adjuvanted …

Background Influenza is associated with a high mortality and morbidity in older adults.
Vaccination remains the most effective method of preventing influenza and its …

Influenza directly or indirectly contributes to the four leading causes of global mortality, at
rates that are highest in older adults. As the proportion of older adults in the Korean …

Safety and immunogenicity of the influenza vaccine adjuvanted with MF59 (FLUADTM) were
compared to those of a non adjuvanted subunit vaccine in elderly subjects during three …

Background The absolute degree of protection from influenza vaccines in older adults has
not been studied since 2001. This study aimed to show the clinical efficacy of an MF59 …